What if biotech peaked in 2018?
Venture deals, IPOs, buyouts, follow-on offerings — they’ve all been on the decline since 2018 in biotech, which could be cause for concern in the sector.
As STAT’s Kate Sheridan reports, a new analysis from BIO illustrates just how volatile biotech has been in recent years. One closely watched biotech index surged 550% from 2009 to 2015 but oscillated so much in the intervening years that it started 2020 back where it was five years ago.
But there are signs that 2018 was something of a zenith. IPOs and venture capital dollars fell in 2019, and, thanks in part to a global pandemic, 2020 might be similarly sluggish. The biggest contrast comes in acquisitions. Where 2018 saw a bevy of high-dollar deals, and 2019 brought a large number of mid-size buyouts, 2020 is “likely to be a down year for acquisitions,” said BIO’s David Thomas, the organization’s vice president of industry analysis.
Read more.
As STAT’s Kate Sheridan reports, a new analysis from BIO illustrates just how volatile biotech has been in recent years. One closely watched biotech index surged 550% from 2009 to 2015 but oscillated so much in the intervening years that it started 2020 back where it was five years ago.
But there are signs that 2018 was something of a zenith. IPOs and venture capital dollars fell in 2019, and, thanks in part to a global pandemic, 2020 might be similarly sluggish. The biggest contrast comes in acquisitions. Where 2018 saw a bevy of high-dollar deals, and 2019 brought a large number of mid-size buyouts, 2020 is “likely to be a down year for acquisitions,” said BIO’s David Thomas, the organization’s vice president of industry analysis.
Read more.
.png)
No hay comentarios:
Publicar un comentario